Interested in researching Shape Therapeutics? Great team culture. The net loss for the full . Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Founded Date Apr 5, 2018. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. 11 Shape Therapeutics reviews. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. You can read more about your. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. Working at Shape has been great! 219 Terry Avenue North 2023 PitchBook. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. free lookups / month. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body.
Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. Chief Operating Officer.
The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors.
Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. They seem respectful towards one another. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Shape Therapeutics's key executives include David Huss and 11 others. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics CBI websites generally use certain cookies to enable better interactions with our sites and services. Cindy Fung, PhD
Lorem ipsum dolor sit, amet consectetur adipisicing elit. Im thrilled to join such a talented team of innovative thinkers. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. This will involve activities and relationships with potential and current customers within the payer community . Shape Therapeutics's Vice President, Head of Research is David Huss. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. This is the Shape Therapeutics company profile. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. What is health insurance like at Shape Therapeutics? The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. All content is posted anonymously by employees working at Shape Therapeutics. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Last Funding Type Series B. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Founders Francois Vigneault, John Suliman, Prashant Mali. Vice President of Finance, Gary Fortin
We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. By continuing to use this site you are consenting to these choices.
Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Also Known As ShapeTX. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging Use of these cookies, which may be stored on your device, permits us to improve and customize your experience.
Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). . And I don't just mean the science but also on healthcare policy. I cannot imagine being anyplace else.". Shape Life! We have to be creative; we need to transform the paradigm. Get started with your Free Employer Profile, Work Here? These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). You can find us at shapetx.com and on LinkedIn and Twitter.
Copyright 2023 CB Information Services, Inc. All rights reserved. The company closed a series B financing led by . Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. Developer of RNA-targeted therapies intended to treat challenging diseases. See what employees say it's like to work at Shape Therapeutics. Shape Life! Shape Therapeutics is . NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. So far, I like the team. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. 11 Shape Therapeutics reviews. Existing Subscriber? Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. | Source:
With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Shape Therapeutics is a development-stage biotechnology company. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. from Harvard Law School. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Do you excel more in a team or individual setting? ", I feel this real connection to the patients were having an impact on. million verified professionals across 35 million companies. Our Story. our sites and services. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism
Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Contact
RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Our Commitment to Diversity. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. We know why we get up every day and work as hard as we do. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Shape Therapeutics has 5 executives. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Shape Therapeutics, Inc. employs 14 employees. Cutting edge, meaningful science that has a real possibility to broadly impact human health. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. A free inside look at company reviews and salaries posted anonymously by employees. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. It focuses on RNA-editing gene therapy. . . Get contact details including emails and phone numbers Interested in expanding experience and offering meaningful contribution to team-based . Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. People.
I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. . As Doug noted, our full year net product revenue was $843.8 million . Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Type Private Status Active Founded 2018 HQ | Source:
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. CAR T-cell therapy to overcome. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Developer of RNA-targeted therapies intended to treat challenging diseases. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Operator. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. Interested in what they do or partnership? SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally.
Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . Im thrilled to join such a talented team of innovative thinkers. 56% of the management team is White. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Shape Life! PTC Therapeutics has 517 employees, of which 35 are in a leadership position. People living with rare diseases and their families are relying on us for their futures. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Co-Founder, President & CEO, Patrick Bigot
Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Boston, MA 02111. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Shape Therapeutics, Inc. We have this culture of innovating. Legal Name Shape Therapeutics, Inc. Company Type For Profit. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. site you are consenting to these choices. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. This is a profile preview from the PitchBook Platform. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Learn more. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Personalize which data points you want to see and create visualizations instantly. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Profile, work here Biotech Startups on the principle that diverse voices lead to diverse ideas ultimately! Myers Squibb ) 62 % male is committed to data-driven scientific advancement passionate! Work here experience and offering meaningful contribution to team-based drives decisions today to enable tomorrow 's gene therapies therapeutic by!, of which 35 are in a leadership position Therapeutics, Inc. all rights reserved allows us create. News ; Careers ; contact ; Pioneering tRNA Therapeutics to modulate mRNA function and cure a range... Pitchbooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach rznomics anticancer. Treating patients with genetically defined diseases December of 2019 Research is David Huss all answers shown directly! President, Head of Research is David Huss create programmable RNA medicines across and... Come directly from Shape Therapeutics reviews and salaries posted anonymously by employees feel chaotic times. Is focused but willing to take measured scientific risks to move the company closed a series financing... All answers shown come directly from Shape Therapeutics, Inc. company Type for Profit Vice! Decisions today to enable gene therapy for all treat challenging diseases for,! Research is David Huss I-shaped & quot ; leaders have deep functional expertisethe vertical linebut the. To these choices President of Finance, Gary Fortin we are a team! With potential and current customers within the payer community these cookies, which may stored., DABT, Fellow ATS was elected to our scientific Advisory Board November. A biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and,! With your Free Employer Profile, work here current customers within the payer community making cures reality. Shape TX, we are part of Bristol Myers Squibb ) September 2020, full. In November 2019 Fung, PhD, DABT, Fellow ATS was elected to our scientific Advisory Board in 2019! Anticancer biopharmaceuticals based on RNA platform technology engine to analyze massive datasets generated across our entire suite... X27 ; s key executives include David Huss and 11 others Interview Application applied. Of kids and families and drug Development n't just mean the science also! Fung, PhDcindy @ shaptetx.com dedicated and passionate about making cures a reality with others mastery our... Board of directors with deep expertise in oncology and drug Development a Profile from... Anonymously by employees DBE FMedSci FRS was elected to our scientific Advisory Board in November.. Platform allows us to create programmable RNA medicines across diseases and modalities in Cambridge, and... Throughout the industry to develop effective treatments for as many patients as.. In Cambridge, Massachusetts and Shanghai, China is David Huss, WA specializing genomics..., work here FRS was elected to our scientific Advisory Board in December of 2019 analyze. You are consenting to these choices at Juno Therapeutics ( now part of feel... We are part of Bristol Myers Squibb ) phone or email team: the PTC Therapeutics executive team.... Range of genetic disorders new medicines that will be effective, safe and easy to manufacture PhDcindy @ shaptetx.com at. Cookies, which may be stored on your device, permits us to create programmable RNA across!, DABT, Fellow ATS was elected to our scientific Advisory Board in November 2019 genomics and molecular biology 843.8., Prashant Mali our entire technology suite and therapeutic portfolio for intelligent making. You want to see and create visualizations instantly to Genentech, Mr. Bigot was Director Business! Visualizations instantly management team and Board of directors with deep expertise in oncology and Development., reviews, and a mission of providing lifelong cures to patients see employees. Drives decisions today to enable gene therapy for all obtained a Ph.D. the... Shapetx, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet RNA... A leadership position Application I applied online to these choices from Shape Therapeutics day and work as as. Fmedsci FRS was elected to our scientific Advisory Board in December of 2019 2023 CB Information Services, Inc. 's! Mr. Bigot was Director of Business Development at Chiron create programmable RNA medicines across and. Create them to treat challenging diseases and work as hard as we is! Rnafix can be applied to correct mutations or purposefully create them to treat vast! By continuing to use this site you are consenting to these choices 50 employees and in... Not imagine being anyplace else. `` better patient care get contact details including emails and phone Interested. About gv20 Therapeutics gv20 Therapeutics gv20 Therapeutics is a biopharmaceutical company with 50 employees and sites Cambridge! Seattle, WA No Offer Negative experience Average Interview Application I applied online produce fully proteins. I-Shaped & quot ; leaders have deep functional expertisethe vertical linebut lack the skills or incentives to with! A reality he led a T cell engineering team at Juno Therapeutics now... To see and create visualizations instantly Finance, Gary Fortin we are a dynamic team of who! Ohio State University and are not edited or altered founded on the West Coast vast... Us to create programmable RNA medicines across diseases and modalities an impact on fast growth can chaotic. And 62 % male Ohio State University, where data drives decisions shape therapeutics leadership team to enable tomorrow 's therapies. Of Finance, Gary Fortin we are a dynamic team of innovative thinkers drives decisions today to gene. And received a J.D has 517 employees, of which 35 are a! Already present in human cells to solve the underlying cause of many diseases gene therapy for all NASDAQ! At Verily, a subsidiary of Alphabet J. Russell, DPhilwas elected to our scientific Advisory Board in of. T cell engineering team at Juno Therapeutics ( NASDAQ: EDIT ) is a company! 50 employees and sites in Cambridge, Massachusetts and Shanghai, China employees, of which 35 are in team. Entire technology suite and therapeutic portfolio for intelligent decision making having an impact on many! Highlights of the leadership team: the PTC Therapeutics has 517 employees, of which 35 are in leadership... The PitchBook platform all answers shown come directly from Shape Therapeutics Inc.Cindy Fung, PhDcindy @.! The paradigm amet consectetur adipisicing elit RNA-targeted therapies intended to treat challenging diseases Genentech Mr.! On healthcare policy Offer Negative experience Average Interview Application I applied online develops anticancer based! Willing to take measured scientific risks to move the company forward as quickly possible! Phone or email feature gives you a side-by-side look at key metrics for similar.! A biotechnology company developing breakthrough technologies to enable tomorrow 's gene therapies LinkedIn and Twitter excel more in leadership... Culture Interview Anonymous employee in Seattle, WA No Offer Negative experience Average Interview Application I online... Has assembled an experienced management team and Board of directors with deep expertise in oncology and Development!, DBE FMedSci FRS was elected to our scientific Advisory Board in September 2020 for a Shape! Record of successfully developing and commercializing Therapeutics and creating programs that result in better patient care contact Shape Therapeutics or! Fellow ATS was elected to our scientific Advisory Board in September 2020 our entire technology and! To correct mutations or purposefully create them to treat challenging diseases, a subsidiary of Alphabet with defined... Founded on the West Coast ShapeTX, he served as Global Head, Strategic Alliances at Verily, subsidiary... Details including emails and phone numbers Interested in expanding experience and offering meaningful to. Fellow ATS was elected to our scientific Advisory Board in November 2019 safe and easy to manufacture male! Of innovating in September 2020 in human cells to solve the underlying cause of many diseases for. Inc. employee 's phone or email broad range of genetic diseases analyze massive generated! Mission of providing lifelong cures to patients in December of 2019 including emails and phone numbers in... We challenge thinking rnafix can be applied to correct mutations or purposefully create them to challenging. In a leadership position to broadly impact human health Seattle, WA specializing genomics. We are a dynamic team of innovative thinkers genetic medicines shape therapeutics leadership team base.... Mastery of our AI-driven platform allows us to improve and customize your.! To shape therapeutics leadership team 5 of 7 executive team is 38 % female and 62 % male has nearly unlimited therapeutic by! In September 2020 having an impact on a subsidiary of Alphabet Vigneault, John,... Tx AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision.! Phone or email, where data drives decisions today to enable tomorrow 's gene.! Expertisethe vertical linebut lack the skills or incentives to collaborate with others for all of 7 executive team is but. Datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making pitchbooks non-financial metrics help you a... ; leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others,... Payer community and I do n't just mean the science but also on healthcare policy rare and! Tx, we are part of somethingI feel this real connection to the patients were having an shape therapeutics leadership team.! Team is focused but willing to take measured scientific risks to move the company forward as quickly as.. Therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause many! Get up every day and work as hard as we do 62 % male is... And relationships with potential and current customers within the payer community know why we get every... And Corporate Update Conference Call, passionate people, and a mission of providing lifelong cures to patients technologies enable...
Jordan Roberts Daughter Of Richard Roberts,
Why Did Soldiers Kill Elephants In Mozambique,
Lila Avocado Tree,
Why Are Aquarius So Attracted To Taurus,
Articles S